Exelixis, Inc. (Nasdaq: EXEL) announced that its Board of Directors has authorized an additional $500 million stock repurchase program, which will be executed before December 31, 2025. This decision reflects the company’s commitment to returning value to shareholders.

The announcement was made on February 20, 2025, and a press release detailing the authorization has been issued. Exelixis continues to focus on strategic financial management while advancing its oncology pipeline.